Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference Read more about Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference
Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting Read more about Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting
Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference Read more about Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications Read more about Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications
Amarin to Present at the Jefferies 2019 Healthcare Conference Read more about Amarin to Present at the Jefferies 2019 Healthcare Conference
U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication Read more about U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting Read more about Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting
Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations Read more about Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations
New Drug Submission Filed for Vascepa® with Health Canada Read more about New Drug Submission Filed for Vascepa® with Health Canada